Positive responses to targeted therapy with RAF inhibitors or with a combination of RAF and MEK inhibitors have been observed predominantly in pediatric brain tumors with BRAF mutation [pylocitic astrocytoma (30), low-grade gliomas (31), and pleomorphic xanthoastrocytoma (32)]. This evidence concerns the gene RAF1 and brain neoplasm.